Mehdi Hamadani: Outpatient administration of every single commercial CAR-T product

Mehdi Hamadani, Director of the BMT and Cellular Therapy Program at the Medical College of Wisconsin, recently shared on X:   .

“Our simplified approach MCW Cancer Center for outpatient administration of every single commercial CAR-T product, Fateeha Furqan.

When I developed it, I argued that we have done autos and allos OP for years and wanted to apply same model. No gimmicks of patients wearing devices, no phone calls, no remote monitoring, no nightly check….

You of course need space:
We see patients daily M-F in Day Hospital (each MD/APP see their own)
Weekends BMT attendings on call see patients
Nights if needed patients are assessed in our 24 hour clinic.

We developed an early CRS management strategy. We give toci for grade 1 CRS; and capable of doing it OP 24/7. This avoid many admissions (details in open access paper).

This is not possible w/o dedicated MDs/APP (Tim Fenske, Nirav Shah, Binod Dhakal, Meera Mohan, Anita D’Souza, Marcelo Pasquini, Sameem Abedin, Lyndsey Runaas et al.)”

Read further.
Source: Mehdi Hamadani/X